Search Results
May 31, 2026, 22:37 ET ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements. Any forward-looking statements contained
More news about: Oricell Therapeutics Holdings Limited
May 31, 2026, 22:14 ET BC.GAME Taps Into Football Fever With Pinball Striker 20000X
separately.The goal area provides the main finish point of each round. If the ball reaches the goal, it can land in one of three jackpot zones: Mini, Major or Grand. The Mini Jackpot pays 20x bet, the Major Jackpot pays 500x bet, and the Grand Jackpot pays 10,000x bet.Pinball Striker 20000X has a stated
More news about: BC.GAME
May 31, 2026, 22:11 ET Crypto Meets Wall Street: MEXC Unveils 'RealStocks' with 0-Fee U.S. Equity Trading and Real Dividends
trading through traditional brokerages, which requires enduring tedious currency exchange and deposit processes. The second was trading synthetic assets or tokenized products on crypto platforms, which often comes with drawbacks like poor liquidity and a lack of dividend payouts. The launch of 'RealStocks'
More news about: MEXC
May 31, 2026, 22:00 ET Crypto Meets Wall Street: MEXC Unveils 'RealStocks' with 0-Fee U.S. Equity Trading and Real Dividends
trading through traditional brokerages, which requires enduring tedious currency exchange and deposit processes. The second was trading synthetic assets or tokenized products on crypto platforms, which often comes with drawbacks like poor liquidity and a lack of dividend payouts. The launch
More news about: MEXC
May 31, 2026, 21:41 ET 【直擊ASCO 2026】亞盛醫藥MDM2-p53抑制劑APG-115兒童實體瘤數據首發，「星光計劃」品種潛力初顯
」此項研究在2026 ASCO年會上展示的核心要點如下：Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)Alrizomadlin（APG-1
More news about: 亞盛醫藥
May 31, 2026, 21:06 ET 【直擊ASCO 2026】亞盛醫藥耐立克®治療CML-LBP與Ph+ BCP-ALL數據發佈，有望填補急變期治療空白
ASCO年會上展示的核心要點如下：Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)奧雷巴替尼（HQP1351）聯合貝林妥歐單抗治療淋系急變期慢性髓細胞白血病（CML-LBP）或費城染色體陽性B細胞前體急性淋巴細胞白血病（Ph+
More news about: 亞盛醫藥
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
combination therapy), n=9: CS2009 was dosed at 20 or 30 mg/kg, Q3W plus docetaxel;(3) Group 3 (1L NSCLC monotherapy ), n=23: CS2009 was dosed at 20 or 30 mg/kg, Q3W;(4) Group 4 (1L squamous NSCLC combination therapy), n=19: CS2009 was dosed at 20 or 30 mg/kg Q3W plus paclitaxel/carboplatin, followed
More news about: CStone Pharmaceuticals
May 31, 2026, 20:15 ET Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.References[1] Qi
More news about: CARsgen Therapeutics
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
Smoking HistoryAmong the 58 patients with EGFR wild-type adenoNSCLC, 30 patients received IBI363 at 0.6 mg/kg Q2W or 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 25 patients received IBI363 at 3 mg/kg Q3W. In the 3 mg/kg dose group, the median PFS reached 4.2 (95%CI 3.0, 7.0) months,
More news about: Innovent Biologics
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
Across Histologies and Particularly in PD-L1 Negative or Low ExpressionPreliminary efficacy data in this study showed an encouraging response rate of IBI363 in combination with PDC in the first-line treatment of NSCLC with PD-L1 negative or low expression. Notably, the 3→1.5 mg/kg dose group
More news about: Innovent Biologics
May 31, 2026, 20:00 ET ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
1×1010 PFU cohort showed a safety profile consistent with the lower-dose 2×109 PFU cohort, with no Grade 4 or 5 TEAEs reported across either dose level, or no deaths attributable to treatment."The presentation of these Phase IIa results at ASCO 2026 marks a meaningful milestone
More news about: ImmVira Group
May 31, 2026, 20:00 ET Carbice and Noctua Partner to Bring Advanced Thermal Pad Technology to DIY PC Builders
cycles, the nanotubes incrementally conform to surface microstructures, enhancing heat transfer rather than losing it to pump-out, dry-out, cracking, or delamination.Clean, repeatable installation: The aluminum backbone keeps the pad rigid enough to handle and the nanotubes are tacky enough
More news about: Carbice Corporation
May 31, 2026, 20:00 ET AMD Bundles Carbice Ice Pad with Ryzen™ 7 5800X3D
loss of contact with the chip over time. Carbice's Ice Pad offers an affordable, maintenance-free solution that eliminates the need for reapplication or ongoing performance monitoring. It uses vertically aligned carbon nanotubes that remain structurally stable, connected, and conductive over time. This
More news about: Carbice Corporation
May 31, 2026, 20:00 ET D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
safety profile consistent with the known profiles of each agent. Grade 3 or higher TRAEs occurred in 32.7% of patients, with most severe events attributable to pembrolizumab, and serious TRAEs reported in 17.3% of patients. No new or unexpected safety signals were identified for elisrasib, and the overall
More news about: D3 Bio
May 31, 2026, 19:30 ET TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026
underlying patient population. The incidence of Grade 3 or higher treatment-related adverse events (TRAEs) observed with the combination of Tosposertib and Keytruda was 48.3%. No Grade 5 treatment-related adverse events leading to patient death or cardiovascular toxicities were reported.Professor
More news about: TiumBio
May 31, 2026, 19:27 ET Scripps Pulls 54 Local Stations from DIRECTV After Seeking Record Retransmission Consent Rates
Spurs will meet for the NBA title next week, as well.Broadcasters like Scripps continue to accumulate exclusive control over local sports teams or other civic content, only to then deny viewers access at times of peak demand. This enables stations to leverage municipal pride and fan loyalties to
More news about: DIRECTV
May 31, 2026, 18:00 ET Web3 Has No Safe AI. DMind AI Just Quantified the Gap -- and KDD 2026 Made It Official.
Youth Student Special ProgramPublished or accepted 10 papers at top venues including KDD, WWW, S&P, and ICLRServed as invited reviewer for NeurIPS, ACL, ICML, and other leading conferencesNamed primary inventor on 8 granted or published invention patentsHis contributions
More news about: DMind AI
May 31, 2026, 18:00 ET Cango Inc. Reports First Quarter 2026 Unaudited Financial Results
the Company's core operating results. The presentation of this non-GAAP financial measures is not meant to be considered in isolation or as a substitute for results or guidance prepared and presented in accordance with U.S. GAAP.The Company compensates for these limitations by reconciling the non-GAAP
More news about: Cango Inc.
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
make no representation as to the accuracy or completeness of the information contained herein or otherwise provided and accept no responsibility or liability, in contract, in tort, in negligence, or otherwise, should the information be found to be inaccurate or incomplete in any respect.Servier
More news about: Servier Pharmaceuticals
May 31, 2026, 16:30 ET Berkshire Hathaway to Acquire Taylor Morrison Home Corporation for $8.5 Billion
to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to a proposed acquisition of Taylor Morrison by Berkshire Hathaway. In connection with this proposed acquisition, Taylor Morrison plans to file one or more
More news about: Taylor Morrison Home Corporation
May 31, 2026, 14:09 ET EQT sets target fund size for EQT Infrastructure VII at EUR 21 billion
herein does not constitute an offer to sell, nor a solicitation of an offer to buy, any security, and may not be used or relied upon in connection with any offer or solicitation. Any offer or solicitation in respect of EQT Infrastructure VII will be made only through a confidential private placement memorandum
More news about: EQT
May 31, 2026, 12:03 ET iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo
may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors or employees to third parties.
More news about: iHuman Inc.
May 31, 2026, 11:00 ET United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026
availability, it can be paired with an automated clinical workflow supported by an 80-slice CT configuration[1], or a 160-slice CT configuration[2] for cardiac and general imaging. The entire uMI Panvivo line is built on the
More news about: United Imaging Healthcare Co., Ltd.
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks
More news about: Akeso, Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21
More news about: Johnson & Johnson